StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) shareholders

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
106M of 94M shares
Institutional holders
319
89 new, 28 sold out
Net institutional buying
16M
In Q2 2026
Insider trades, 12 months
0 buys · 118 sales
Net sold $110.40M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Janus Henderson Group PLC10,599,66011.90%13G (passive) amendmentSep 30, 2025
Abigail P. Johnson
Joint filing with FMR LLC (7.70%)
7,142,4827.70%13G (passive) amendmentJun 30, 2026
Steven Boyd
Joint filing with Armistice Capital, LLC (7.52%)
6,724,0007.52%13G (passive) amendmentSep 30, 2025
BlackRock, Inc.6,689,4357.50%13G (passive) amendmentMar 31, 2025
FMR LLC
Joint filing with Abigail P. Johnson (6.10%)
5,707,8836.10%13G (passive) amendmentSep 30, 2026
Bank Of America Corp /De/5,439,1555.80%13G (passive)Jun 30, 2026
Perceptive Advisors LLC
Joint filing with Joseph Edelman (5.50%), Perceptive Life Sciences Master Fund, Ltd. (5.50%)
4,895,6155.50%13G (passive)Oct 6, 2025
Macquarie Management Holdings Inc
Joint filing with Macquarie Group Limited (5.41%), Macquarie Investment Management Business Trust (5.41%)
4,797,3145.41%13G (passive) amendmentMar 31, 2025
Vanguard Capital Management4,699,4245.09%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of TVTXValueChange% of portfolio
Jupiter Topco LLC11,324,19112.01%$643.30MNew0.26%
BlackRock, Inc.8,020,6638.51%$455.65M+228,6300.01%
FMR LLC7,096,6147.53%$403.16M−3,871,3530.02%
Bank Of America Corp /De/4,568,3414.85%$259.53M+3,223,2300.02%
State Street Corp4,256,2244.52%$241.80M−703,7640.01%
Vanguard Capital Management LLC4,108,6944.36%$233.41M+62,8820.00%
Perceptive Advisors LLC3,752,5743.98%$213.18M−389,9773.20%
Nomura Asset Management International Inc.2,812,5142.98%$159.78M−457,9990.24%
Adage Capital Partners Gp, L.L.C.2,569,3562.73%$145.97M+1,592,3560.20%
Geode Capital Management, LLC2,371,8872.52%$134.77M+2,3280.01%
Rock Springs Capital Management LP2,179,0692.31%$123.79M+701,1156.04%
Kynam Capital Management, LP2,000,0002.12%$113.62M+430,9826.28%
Stephens Investment Management Group LLC1,875,3041.99%$106.54M+76,8381.14%
Renaissance Technologies LLC1,833,0791.94%$104.14M−133,7000.14%
Emerald Advisers, LLC1,600,8861.70%$90.95M+43,6902.14%
Armistice Capital, LLC1,572,5391.67%$89.34M−3,324,8781.09%
Two Sigma Investments, LP1,565,6561.66%$88.94M+57,3970.06%
Vanguard Portfolio Management LLC1,541,6171.64%$87.58M−167,5220.00%
Goldman Sachs Group Inc1,535,3211.63%$87.22M−184,4000.01%
Wellington Management Group Llp1,533,0801.63%$87.09M+510,8080.02%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026319106M100.0%89 / 12186 / 2832M16M
Q1 2026261101M100.0%49 / 9093 / 5920M14M
Q4 2025278102M100.0%77 / 9094 / 3521M20M
Q3 2025238101M100.0%55 / 7479 / 2718M17M
Q2 2025212101M100.0%41 / 7570 / 4617M14M
Q1 202521898M100.0%45 / 8955 / 2319M14M
Q4 202419795M100.0%48 / 7453 / 2824M13M
Q3 202417884M88.8%29 / 6257 / 2422M19M
Q2 202417489M94.4%30 / 7250 / 2812M18M
Q1 202417595M100.0%31 / 6547 / 2113M8M
Q4 202316590M95.7%32 / 5852 / 3621M14M
Q3 202316983M87.6%35 / 6649 / 3422M21M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

289 funds held TVTX in Q2 2026, 33% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of TVTXValue% of fundAs of
Vanguard Total Stock Market Index Fund2,947,8903.13%$167.47M0.01%Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund2,580,3882.74%$121.74M0.05%May 31, 2026
iShares Russell 2000 ETF2,294,9532.43%$130.38M0.16%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2,130,1352.26%$121.01M1.13%Jun 30, 2026
Nomura Small Cap Core Fund2,086,0172.21%$98.42M1.78%May 29, 2026
Vanguard Explorer Fund1,431,3311.52%$80.00M0.36%Jul 31, 2026
Janus Henderson Global Life Sciences Fund1,413,1171.50%$80.28M1.38%Jun 30, 2026
Janus Henderson Triton Fund1,118,3211.19%$63.53M1.07%Jun 30, 2026
Vanguard Extended Market Index Fund1,066,3721.13%$60.58M0.06%Jun 30, 2026
Fidelity Small Cap Index Fund977,0061.04%$54.60M0.16%Jul 31, 2026
Fidelity Blue Chip Growth Fund913,9230.97%$51.08M0.05%Jul 31, 2026
iShares Russell 2000 Growth ETF825,3750.88%$46.89M0.30%Jun 30, 2026
Select Biotechnology Portfolio798,8430.85%$37.69M0.72%May 31, 2026
Fidelity Small Cap Growth Fund743,2900.79%$41.54M0.47%Jul 31, 2026
iShares Biotechnology ETF640,4210.68%$36.38M0.40%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Eric M. DubeCHIEF EXECUTIVE OFFICER, Director432,8860.46%Oct 19, 2026
Peter HeermaEVP, CHIEF COMMERCIAL OFFICER117,0660.12%Sep 17, 2026
Elizabeth E. ReedChief Legal Officer and GC142,8890.15%Sep 17, 2026
Jula InrigEVP, Head of R&D & CMO102,4910.11%Sep 17, 2026
Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER47,7280.05%Sep 17, 2026
William E. RoteChief Research Officer98,1970.10%Sep 17, 2026
Christopher R. ClineCHIEF FINANCIAL OFFICER87,9080.09%Sep 17, 2026
Jeffrey A. MecklerDirector109,8000.12%Sep 11, 2026
Gary A. LyonsDirector62,4000.07%Aug 19, 2026
Roy D. BaynesDirector46,0000.05%Jun 16, 2026
Timothy CoughlinDirector56,2500.06%Jun 16, 2026
Brinkley Ruth WilliamsDirector29,7500.03%May 21, 2026
Suzanne Louise BruhnDirector32,7500.03%May 21, 2026
Ron SquarerDirector39,3750.04%May 21, 2026
Sandra PooleDirector34,0000.04%May 21, 2026
John A. OrwinDirector39,3750.04%May 21, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Oct 15, 2026Sale(10b5-1 plan)−78,400$55.02$4.31M432,886
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Oct 15, 2026Sale(10b5-1 plan)−37,270$54.20$2.02M511,286
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Oct 15, 2026Sale(10b5-1 plan)−128,065$52.97$6.78M548,556
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Oct 15, 2026Option exercise+200,000$8.93$1.79M676,621
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Oct 15, 2026Option exercise+43,735$26.88$1.18M476,621
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 17, 2026Sale(10b5-1 plan)−101,691$64.59$6.57M439,688
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 17, 2026Option exercise+108,493$23.34$2.53M541,379
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 17, 2026Sale(10b5-1 plan)−6,802$64.95$441.79K432,886
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 17, 2026Sale(10b5-1 plan)−8,282$65.07$538.91K117,066
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 17, 2026Option exercise+8,282$22.40$185.52K125,348
William E. Rote
Chief Research Officer
Sep 16, 2026Sale(10b5-1 plan)−47,746$63.61$3.04M98,197
William E. Rote
Chief Research Officer
Sep 16, 2026Sale(10b5-1 plan)−65,104$63.12$4.11M145,943
William E. Rote
Chief Research Officer
Sep 16, 2026Option exercise+57,500$26.88$1.55M211,047
William E. Rote
Chief Research Officer
Sep 16, 2026Option exercise+55,000$15.46$850.30K153,547
William E. Rote
Chief Research Officer
Sep 16, 2026Option exercise+350$17.96$6.29K98,547
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 16, 2026Option exercise+195,841$23.34$4.57M628,727
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 16, 2026Sale(10b5-1 plan)−96,125$63.64$6.12M432,886
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 16, 2026Sale(10b5-1 plan)−99,716$63.26$6.31M529,011
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 16, 2026Option exercise+100,000$11.25$1.13M217,066
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 16, 2026Sale(10b5-1 plan)−79,113$63.65$5.04M117,066
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 16, 2026Sale(10b5-1 plan)−93,604$63.25$5.92M196,179
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 16, 2026Option exercise+17,717$26.88$476.23K289,783
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 16, 2026Option exercise+55,000$15.46$850.30K272,066
Christopher R. Cline
CHIEF FINANCIAL OFFICER
Sep 15, 2026Sale(10b5-1 plan)−1,900$63.69$121.01K87,908
Christopher R. Cline
CHIEF FINANCIAL OFFICER
Sep 15, 2026Sale(10b5-1 plan)−20,735$62.61$1.30M89,808
Christopher R. Cline
CHIEF FINANCIAL OFFICER
Sep 15, 2026Sale(10b5-1 plan)−400$65.31$26.12K87,508
Christopher R. Cline
CHIEF FINANCIAL OFFICER
Sep 15, 2026Option exercise+20,000$17.44$348.80K138,016
Christopher R. Cline
CHIEF FINANCIAL OFFICER
Sep 15, 2026Sale(10b5-1 plan)−27,473$62.00$1.70M110,543
Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026Option exercise+1,625$20.46$33.25K47,728
Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026Sale(10b5-1 plan)−800$62.85$50.28K42,653
Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026Sale(10b5-1 plan)−4,275$62.14$265.65K43,453
Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026Sale(10b5-1 plan)−300$63.66$19.10K42,353
Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026Option exercise+1,250$22.40$28.00K46,103
Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026Option exercise+2,500$27.50$68.75K44,853
William E. Rote
Chief Research Officer
Sep 15, 2026Option exercise+39,650$17.96$712.11K194,395
William E. Rote
Chief Research Officer
Sep 15, 2026Option exercise+39,000$25.25$984.75K154,745
William E. Rote
Chief Research Officer
Sep 15, 2026Sale(10b5-1 plan)−270$65.31$17.63K98,197
William E. Rote
Chief Research Officer
Sep 15, 2026Sale(10b5-1 plan)−3,000$63.65$190.95K98,467
William E. Rote
Chief Research Officer
Sep 15, 2026Sale(10b5-1 plan)−29,021$62.66$1.82M101,467
William E. Rote
Chief Research Officer
Sep 15, 2026Sale(10b5-1 plan)−63,907$61.99$3.96M130,488
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 15, 2026Sale(10b5-1 plan)−270$65.31$17.63K432,886
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 15, 2026Sale(10b5-1 plan)−3,102$63.64$197.41K433,156
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 15, 2026Sale(10b5-1 plan)−28,796$62.66$1.80M436,258
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 15, 2026Sale(10b5-1 plan)−63,498$61.99$3.94M465,054
Eric M. Dube
CHIEF EXECUTIVE OFFICER, Director
Sep 15, 2026Option exercise+95,666$23.34$2.23M528,552
Jula Inrig
EVP, Head of R&D & CMO
Sep 15, 2026Sale(10b5-1 plan)−17,284$62.62$1.08M102,491
Jula Inrig
EVP, Head of R&D & CMO
Sep 15, 2026Sale(10b5-1 plan)−1,600$63.69$101.90K100,891
Jula Inrig
EVP, Head of R&D & CMO
Sep 15, 2026Sale(10b5-1 plan)−400$65.31$26.12K100,491
Jula Inrig
EVP, Head of R&D & CMO
Sep 15, 2026Sale(10b5-1 plan)−25,390$62.02$1.57M119,775
Jula Inrig
EVP, Head of R&D & CMO
Sep 15, 2026Option exercise+32,395$8.93$289.29K145,165
Elizabeth E. Reed
Chief Legal Officer and GC
Sep 15, 2026Option exercise+37,500$15.46$579.75K142,889
Elizabeth E. Reed
Chief Legal Officer and GC
Sep 15, 2026Sale(10b5-1 plan)−21,926$62.03$1.36M120,963
Elizabeth E. Reed
Chief Legal Officer and GC
Sep 15, 2026Sale(10b5-1 plan)−13,874$62.63$868.93K107,089
Elizabeth E. Reed
Chief Legal Officer and GC
Sep 15, 2026Sale(10b5-1 plan)−300$65.31$19.59K105,389
Elizabeth E. Reed
Chief Legal Officer and GC
Sep 15, 2026Sale(10b5-1 plan)−1,400$63.69$89.17K105,689
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026Option exercise+39,283$26.88$1.06M181,349
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026Option exercise+1,381$22.40$30.93K182,730
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026Option exercise+36,526$8.93$326.18K219,256
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026Sale(10b5-1 plan)−71,938$62.05$4.46M147,318
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026Sale(10b5-1 plan)−27,421$62.59$1.72M119,897

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
10.30%
10M shares short
Days to cover
4.7
At 2M shares a day
Change since last report
-12.4%
From 11M shares
Short volume, 20 days
53.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Travere Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 455,906 shares on Sep 17, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Eric M. Dube
Director, Officer
Oct 15, 2026243,735$12.98MOct 15, 2026Exercise of Stock Options
Eric M. Dube
Director, Officer
Sep 17, 2026108,493$6.89MSep 17, 2026Exercise of Stock Options
Peter Heerma
Officer
Sep 17, 20268,282$525.74KSep 17, 2026Exercise of Stock Options
Eric M. Dube
Director, Officer
Sep 16, 2026195,841$12.24MSep 16, 2026Exercise of Stock Options
Peter Heerma
Officer
Sep 16, 2026172,717$10.80MSep 16, 2026Exercise of Stock Options
William E. Rote
Officer
Sep 16, 2026112,850$7.05MSep 16, 2026Exercise of Stock Options
Sandra Calvin
Officer
Sep 15, 20265,375$353.62KSep 15, 2026Exercise of Stock Options
Christopher R. Cline
Officer
Sep 15, 202650,508$3.32MSep 15, 2026Exercise of Stock Options
Elizabeth E. Reed
Officer
Sep 15, 202639,576$2.60MSep 15, 2026Exercise of Stock Options
Eric M. Dube
Director, Officer
Sep 15, 202695,666$6.29MSep 15, 2026Exercise of Stock Options
Peter Heerma
Officer
Sep 15, 2026102,190$6.72MSep 15, 2026Exercise of Stock Options
William E. Rote
Officer
Sep 15, 202696,198$6.33MSep 15, 2026Exercise of Stock Options
Jula Inrig
Officer
Sep 15, 202644,674$2.94MSep 15, 2026Exercise of Stock Options
Jeffrey A. Meckler
Director
Sep 10, 202620,000$1.32MSep 10, 2026Exercise of Stock Options
Gary A. Lyons
Director
Aug 18, 20265,000$317.65KAug 18, 2026Exercise of Stock Options

See a number that looks wrong?